Remove Branding Remove Drugs Remove Life Science Remove Pharma Companies
article thumbnail

Top Life Science News and Trends in 2023 at Xtalks

XTalks

In 2023, there were significant advancements and notable trends in the life sciences. These advancements and trends addressed important industry challenges and offered opportunities to foster innovations and solutions in areas including drug development, healthcare and medical devices.

article thumbnail

ODAIA wins $25m funding to boost commercial insights platform for pharma

Pharmaceutical Technology

ODAIA, a life sciences predictive analytics and commercial insights provider, has secured an investment of $25m in its Series B funding round. This software-as-a-service (SaaS) platform is also used by life science brands to launch their drugs, therapeutics and vaccines in the markets, using data-driven solution.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

3 ways pharma marketers can draw inspiration from digitally-native brands

pharmaphorum

As pharmaceutical marketers prepare their brands for the future, there are a number of important ways they can learn from digitally-native brands. Analysing the world of digitally-native brands highlights three standout ways in which parts of their approach could be brought to the pharmaceutical world. Be more agile .

Branding 130
article thumbnail

Disruption in healthcare is coming

World of DTC Marketing

PBMs, insurers, pharma companies, and hospitals don’t want to give up their profits even if it’s better for the general population. The company has hired former senior health regulators to help it navigate America’s healthcare bureaucracy. . Then there is the cost of generic drugs.

Pharmacy 227
article thumbnail

Nine new industry collaborations driving drug discovery forward

Drug Discovery World

Closed Loop Medicine and Pharmanovia TechBio Closed Loop Medicine and pharma company have initiated the OptiZest study and recruited the first patient. The focus of the collaboration has been on developing predictive AI models of stem cell-derived organoids to replace animal models in drug discovery and precision medicine.

Drugs 52
article thumbnail

Changes to UK Statutory Scheme go ahead despite pharma criticism

Drug Discovery World

The UK government has published new terms for the Statutory Scheme for branded medicines, which controls the prices of medicines paid by the NHS. This means that companies will pay a rebate on the sales of branded medicines to the NHS of 21.9% in 2024, 24% in 2025 and 26.8% in Spain and 8.25% in Ireland.

article thumbnail

AbbVie, Lilly pull out of UK voluntary drug pricing agreement

pharmaphorum

Two top pharma companies have exited the UK’s voluntary medicines pricing agreement in protest at what the industry has said is a “punitive” system of revenue clawbacks, casting doubt on the future of the scheme in its present form.